Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the <scp>OPERA</scp> cohort

20250 citationsJournal Articlehybrid Open Access

Authors

Gerald Pierone · Oyster Point Family Health Center

Laurence Brunet · GridBridge (United States)

Jennifer S Fusco · GridBridge (United States)

Michael Sension · Henderson Behavioral Health

Megan S. Dunbar · Gilead Sciences (United States)

Joshua Gruber · Gilead Sciences (United States)

Douglas T. Dieterich

Abstract

In this large US cohort, both B/F/TAF and DTG/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG/3TC tended to be discontinued faster than B/F/TAF.

Topics & Keywords

HIV/AIDS drug development and treatment Hepatitis C virus research Hepatitis B Virus Studies

Publication Details

Published in: HIV Medicine

Volume 26, Issue 11, pp. 1707-1716

DOI: 10.1111/hiv.70105

Field-Weighted Citation Impact: 0.00

Command Palette

Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the <scp>OPERA</scp> cohort

Authors

Abstract

Topics & Keywords

Publication Details